Clinical Trial Update: Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety of BMS-986259 in participants with acute decompensated heart failure; study completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Heart Failure

Drugs mentioned

• BMS-986259

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Acute Decompensated Heart Failure | Phase 2 | Status: COMPLETED | Results posted: 2022-08-04